Novo Nordisk's Next Quarter Hinges on a Growth Forecast Nobody Has Confirmed
Published on 10/23/2026 at 16:40 | Editorial boerse-global.de
Ahead of Novo Nordisk's nine-month report on 4 November, the market has latched onto a single hope: that the Danish drugmaker might nudge its growth guidance a little higher. Bankers were said to be counting on exactly that step when the figures land, according to media reports circulating yesterday. Investors should treat it for what it is — an expectation, not a confirmed change in outlook.
Whether the numbers can carry that optimism is the open question. A modest upgrade would validate the reported confidence; its absence would remove the very surprise the recent bullishness rests on. What the bar for a convincing release actually looks like cannot be inferred from talk of a slight raise alone.
BMO Takes the Other Side of the Trade
Not everyone is leaning toward optimism. On 12 October, BMO Capital's Evan Seigerman cut his price target to $40 from $47 while keeping a "Market Perform" rating, pointing to headwinds for Ozempic. That call shifts the focus from a possible guidance lift to pressure inside the business — and the two views are not mutually exclusive. Anticipating an upgrade does nothing to refute the headwind BMO flagged.
For the upcoming release, that leaves a specific checkpoint: the direction of the outlook matters, but so does how management frames the Ozempic drag.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A Cheap Multiple Meets Falling Estimates
The bull case got a fresh voice yesterday when columnist Eric Fry came out in favor of owning Novo Nordisk. His argument pairs a modest valuation with the commercial traction of the Wegovy pill. On his numbers, Novo trades at a price-to-earnings ratio of roughly 14, against 34 for Eli Lilly. Fry sees scope for the stock to double, though he is careful to say that is no certainty.
A discount on its own does not settle the investor's real question. It can be an opportunity if the business stabilizes; if earnings estimates keep sliding, the gap loses much of its meaning. Consensus, as tracked by Zacks, points the wrong way: revenue is expected to fall about 3% in 2026 versus the prior year, with earnings per share down roughly 14%.
So two perspectives sit side by side. Fry is betting on a recovery in the share price. The estimates suggest that success for individual products has yet to translate into improvement at group level.
Prescriptions Are Not Profits
The most tangible plank of Fry's thesis is volume: some 5 million US prescriptions for the Wegovy pill in the first six months, which by his account amounts to about 76% of the American oral obesity market. That shows Novo is already reaching patients with the tablet. Prescription counts, however, are not direct proof that group profit is climbing.
CagriSema: Promise, With Caveats
CagriSema adds another dimension. Novo Nordisk maintains that the drug matters for earnings growth in the years ahead, even as analysts stay skeptical; one expects a notably rapid US launch once approval comes. The FDA decision is anticipated in the fourth quarter of 2026, with Novo projecting a market debut in early 2027. An expectation is not an approval — CagriSema is not yet cleared in the US.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Late analyses of the REDEFINE 1 trial offer further context. Among women, CagriSema was associated with an average weight loss of 25.0% after 68 weeks, against 3.0% on placebo. The evaluation covered 2,309 women. Novo itself labeled these analyses as hypothesis-generating and pointed to a need for further research, so they do not dissolve the uncertainty around near-term trading.
Two Clocks, One Verdict
Investors are therefore watching on different time horizons. CagriSema speaks to the longer product story; the imminent figures must carry the hope for a better growth outlook. A confirmed change in guidance would be sturdier ground than the expectation reported so far — and until 4 November, that is all it is.
Ad
Novo Nordisk Stock: New Analysis - 23 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
